Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: Evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy

Future Microbiology

Volumn 10, Issue 7, 2015, Pages 1111-1123

  Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

anaerobes; delafloxacin; fluoroquinolone; gonorrhea; MRSA; pneumonia; skin and skin structure infection; Staphylococcus aureus; Streptococcus pneumoniae

Indexed keywords

CIPROFLOXACIN; DELAFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PAIN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; ANAEROBIC BACTERIUM; BACTERIAL INFECTIONS; BIOFILM; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME;

BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; BIOFILMS; CLINICAL TRIALS, PHASE III AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME;

EID: 84946569966     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.39     Document Type: Review

References (71)

1. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti Infect. Ther. 11(3), 297-308 (2013
2. Kang CI, Song JH. Antimicrobial resistance in Asia: current epidemiology and clinical implications. Infect. Chemother. 45(1), 22-31 (2013
3. Molton JS, Tambyah PA, Ang BSP, Ling ML, Fisher DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin. Infect. Dis. 56(9), 1310-1318 (2013
4. Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol. 5, 551 (2014
5. Nation RL, Li J. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22(6), 535-543 (2009
6. Mouton JW, Ambrose PG, Canton R, et a.l. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist. Updat. 14(2), 107-117 (2011
7. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J. Antibiot. (Tokyo) 66(10), 571-591 (2013
8. Anstead GM, Cadena J, Javeri H. Treatment of infections due to resistant Staphylococcus aureus. Methods Mol. Biol. 1085, 259-309 (2014
9. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 4(2), 185-191 (2013
10. Van Bambeke F. Renaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolones. Ann. Med. 46(7), 512-529 (2014
11. Emami S, Shafiee A, Forounmadi A. Quinolones: recent structural and clinical developments. Ir. J. Pharm. Res. 4(3), 123-136 (2005
12. Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin. Microbiol. Infect. 11(4), 256-280 (2005
13. Yazaki A, Niino Y, Ohshita Y, et a.l. WO1996JP02710 19960920(US5998436) (1999
14. Goldstein EJC, Citron DM, Merriam CV, et a.l. In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob. Agents Chemother. 47(9), 3008-3011 (2003
15. Zhanel GG, Palatnick L, Nichol KA, et a.l. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997-2002. Antimicrob. Agents Chemother. 47(6), 1867-1874 (2003
16. Harnett SJ, Fraise AP, Andrews JM, et a.l. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. J. Antimicrob. Chemother. 53(5), 783-792 (2004
17. Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47(6), 1875-1881 (2003
18. Nilius AM, Shen LL, Hensey-Rudloff D, et a.l. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob. Agents Chemother. 47(10), 3260-3269 (2003
19. Hammerschlag MR, Roblin PM. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae. J. Antimicrob. Chemother. 54(1), 281-282 (2004
20. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 47(12), 3973-3975 (2003
21. Frean J, Klugman KP, Arntzen L, Bukofzer S. Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents. J. Antimicrob. Chemother. 52(2), 294-296 (2003
22. Tomioka H, Sato K, Kajitani H, Akaki T, Shishido S. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against mycobacterium tuberculosis and mycobacterium avium complex. Antimicrob. Agents Chemother. 44(2), 283-286 (2000
23. Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother. 48(7), 2771-2777 (2004
24. Duffy E, Devito JA, Remy J, Burak E. Delafloxacin chemical properties lead to increased potency against Gram-positive pathogens, including quinolone-resistant pathogens II. Preseneted at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). MA, USA, 12-15 September 2010 (Abstract E183
25. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-Gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob. Agents Chemother. 55(2), 649-658 (2011
26. Burak E, DeVito JA, Remy J, Duffy E. Delafloxacin chemical properties lead to increased potency against Gram-positive pathogens, including quinolone-resistant pathogens I. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). MA, USA, 12-15 September 2010 (Abstract E182
27. So W, Crandon JL, Nicolau DP. Effects of urine matrix and pH on the potency of delafloxacin and ciprofloxacin against urogenic E. coli and K. pneumonia. J. Urol. doi: 10.1016/j.juro.2015.01.094 (2015) (Epub ahead of print
28. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61(3), 377-392 (1997
29. Alam MM, Kobayashi N, Uehara N, Watanabe N. Analysis on distribution and genomic diversity of high-level antiseptic resistance genes qacA and qacB in human clinical isolates of Staphylococcus aureus. Microb. Drug Resist. 9(2), 109-121 (2003
30. Costa SS, Falcao C, Viveiros M, et a.l. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol. 11, 241 (2011
31. Munoz-Bellido JL, Alonzo MM, Martinez Andres JA, et a.l. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob. Agents Chemother. 43(2), 354-356 (1999
32. Garvey MI, Baylay AJ, Wong RL, Piddock LJ. Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 55(1), 190-196 (2011
33. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43(1), 187-189 (1999
34. Van Bambeke F, Glupczynski Y, Plesiat P, Pechere JC, Tulkens PM. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J. Antimicrob. Chemother. 51(5), 1055-1065 (2003
35. Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc. Natl Acad. Sci. USA 99(8), 5638-5642 (2002
36. Robicsek A, Strahilevitz J, Jacoby GA, et a.l. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat. Med. 12(1), 83-88 (2006
37. Remy JM, Tow-Keogh CA, McConnell TS, Dalton JM, Devito JA. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J. Antimicrob. Chemother. 67(12), 2814-2820 (2012
38. Kurz SG, Duffy E, Balthazar J, Bomono RA, Shafer WM. Delafloxacin exerts potent anti-gonococcal activity despite mutations that decrease antibiotic susceptibility due to target modification or drug efflux. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. DC, USA, C-1399 (2014
39. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44(5), 681-688 (2007
40. Remy J, Marra A, Duffy E. Evaluation of the potential for delafloxacin resistance development in Neisseria gonorrhoeae. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. DC, USA, 6-9 September 2014 (Abstract C-1412a
41. Lawrence L, Pillar C, Sahm D, Burak E. In vitro activity of delafloxacin against European isolates of Staphylococcus aureus from skin and soft tissue, respiratory, urine and blood specimens. Presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases & 27th International Congress of Chemotherapy. Milan, Italy, 7-10 May 2011 (Abstract P-1185
42. Lawrence L, Hopkins S, Sahm D, et a.l. Characterization and In vitro Activity of delafloxacin (DLX) against isolates from a phase 2 study of acute bacterial skin and skin structure infections (ABSSSI). Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CA, USA, 9-12 September 2012 (Abstract E-208
43. Weinrick B, Dunman PM, McAleese F, et a.l. Effect of mild acid on gene expression in Staphylococcus aureus. J. Bacteriol. 186(24), 8407-8423 (2004
44. Lawrence L, Benedict M, Hart J, et a.l. Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjets. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). IL, USA, 17-20 September 2011 (A2-045a
45. Lawrence L, Longcor J, Li D, et a.l. Metabolism and mass balance of [14C]-Delafloxacin in healthy human volunteers following intravenous administration. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).CA, USA, 9-12 September 2012 (Abstract A1956
46. Rubino CM, Bhavnani SM, Burak E, Ambrose PG. Pharmacokinetic-pharmacodynamic target attainment analyses supporting delafloxacin phase 3 dose regimen decisions. Poster presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. MA, USA, 12-15 September 2010 (Poster A1-681
47. Hoover R, Lawrence L, Benedict M, et a.l. Pharmacokinetics and relative bioavailability of intravenous and oral formulations of delafloxacin (DLX) in healthy subjects. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. DC, USA, 5-9 September 2014 (Abstract A-682
48. Hoover R, Lawrence L, Benedict M, et a.l. Pharmacokinetics of a 900 mg oral formulation of delafloxacin (DLX) healthy subjects supporting a gonorrhea phase 3 study. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. DC, USA, 5-9 September 2014 (Abstract A-056a
49. Hoover R, Lawrence L, Benedict M, et a.l. A Phase 1, open-label, crossover study to determine the effect of food on the pharmacokinetics of a single dose of oral delafloxacin (DLX) in healthy subjects. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. DC, USA, 5-9 September 2014 (Abstract A-683
50. Hoover R, Lawrence L, Longcor J, Greenfield J. Pharmacokinetics (PK) of pelafloxacin (DLX), vancomycin (VAN), and linezolid (LNZ) in a phase 2 exploratory study in subjects with acute bacterial skin and skin structure infections (ABSSSI). Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CA, USA, 9-12 September 2012 (Abstract A1957
51. Hoover R, Lawrence L, Smith C, Longcor J. Pharmacokinetics (PK) of delafloxacin (DLX) in patients with varying degrees of renal impairment. Presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CO, USA, 10-13 September 2013 (Abstract A-017E
52. Ding Y, Villet MA, Lee JC, Hooper DC. Treatment of renal abscesses caused by Staphylococcus aureus MW2, using delafloxacin and moxifloxacin. Presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases & 27th International Congress of Chemotherapy. Milan, Italy, 10 May 2011 (Poster P1506
53. Marra A, Bortolon E, Molstad D, et a.l. Evaluation of delafloxacin in rat granuloma pouch infections caused by Gram-negative pathogens. Presented at; 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). MA, USA, 12-15 September 2010 (Abstract A1-680
54. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46(5), 669-683 (2000
55. Burak E, Bortolon E, Molstad D, et a.l. Pharmacokinetics and pharmacodynamics of delafloxacin in S. aureus murine thigh infection models. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 12-15 September 2009 (Abstract A1-1941
56. Firsov AA, Vostrov SN, Lubenko IY, et a.l. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J. Antimicrob. Chemother. 54(1), 178-186 (2004
57. Firsov AA, Alferova IV, Smirnova MV, et a.l. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int. J. Antimicrob. Agents 25(5), 409-413 (2005
58. Zinner SH, Vostrov SN, Alferova IV, et a.l. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. Int. J. Antimicrob. Agents 24(2), 173-177 (2004
59. Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol. 17(2), 59-65 (2009
60. Archer NK, Mazaitis MJ, Costerton JW, et a.l. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence 2(5), 445-459 (2011
61. Seral C, Carryn S, Tulkens PM, Van Bambeke F. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J. Antimicrob. Chemother. 51(5), 1167-1173 (2003
62. Vallet CM, Marquez B, Ngabirano E, et a.l. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. Int. J. Antimicrob. Agents 38(3), 249-256 (2011
63. Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 57(6), 2726-2737 (2013
64. Siala W, Mingeot-Leclercq MP, Tulkens PM, et a.l. Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 58(11), 6385-6397 (2014
65. ORiordan W, Mehra P, Manos P, et a.l. A randomized Phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int. J. Infect. Dis. 30C, 67-73 (2014
66. Longcor J, Lawrence L, Duffy E, Hopkins S. Objective measures of clinical efficacy in a Phase 2B Exploratory Study of delafloxacin (DLX) compared to vancomycin (VAN) and linezolid (LNZ) in adults with acute bacterial skin and skin structure infections (ABSSSI). Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CA, USA, 9-12 September 2012 (Abstract L1-1667c
67. Longcor J, Hopkins S, Lawrence L, et a.l. Results of a Phase 2 study of delafloxacin (DLX) compared to vancomycin (VAN) and linezolid (LNZ) in acute bacterial skin and skin structure infections (ABSSSI). Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CA, USA, September 2012 (Abstract L1-1663 9-12
68. Longcor J, Hopkins S, Lawrence L, et a.l. Results of a phase 2 study of delafloxacin (DLX) compared with vancomycin (VAN) and linezolid (LNZ) in acute bacterial skin and skin structure infections (ABSSSI). Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CA, USA, 9-12 September 2012 (Abstract L1-1663
69. Lawrence L, Benedict M, Litwin J, et a.l. A thorough Phase 1 QTc study of delafloxacin (DLX) compared with placebo and moxifloxacin (MXF). Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CA, USA, 9-12 September 2012 (Abstract A1958
70. Deshpande A, Pant C, Jain A, Fraser TG, Rolston DDK. Do fluoroquinolones predispose patients to Clostridium difficile associated disease?. A review of the evidence. Curr. Med. Res. Opin. 24(2), 329-333 (2008
71. Soge OO, Roberts MC, Lenderman C, et a.l. Evaluation of In vitro activity of delafloxacin against contemporary neisseria gonorrhoeae isolates. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. DC, USA, 5-9 September 2014 (Abstract C-1401